| Term 
 
        | -Inotropic Drugs -Increases the Ca levels in the heart muscle- Increases contractility- Increases CO- Increases renal blood flow-Increases renin production- Prevents activation of the reninangiotensin system- Increases urine output- Increases BV- Increases heart's workload. |  | Definition 
 | 
        |  | 
        
        | Term 
 
        | Cardiotonic Agents:   Cardiac Glycosides Prototype:_____ |  | Definition 
 
        | Digoxin (Lanoxin) "Dig"   *originally derived from the foxglove plant. |  | 
        |  | 
        
        | Term 
 
        | Cardiotonic Agents:   Cardiac Glycosides Prototype: Digoxin (Lanoxin) "Dig"   Indications (2): |  | Definition 
 | 
        |  | 
        
        | Term 
 
        | Cardiotonic Agents:   Cardiac Glycosides Prototype: Digoxin (Lanoxin) "Dig"   Actions (2): |  | Definition 
 
        | 
Positive Inotrope, Negative Chronotrope, Negative DromotropeDiuretic Effect (NOT a diuretic) |  | 
        |  | 
        
        | Term 
 
        | Cardiotonic Agents:   Cardiac Glycosides Prototype: Digoxin (Lanoxin) "Dig"   Adverse Effects (7): |  | Definition 
 
        | 
HypotensionBradycardiaWeakness & drowsinessHeadacheVision changes (yellow halo, blurring, spots/threads)arrhythmiasGI Upset |  | 
        |  | 
        
        | Term 
 
        | Cardiotonic Agents:   Cardiac Glycosides Prototype: Digoxin (Lanoxin) "Dig"   Normal therapeutic dose: |  | Definition 
 
        | 0.125mg-0.25mg   *Very close to toxic dose |  | 
        |  | 
        
        | Term 
 
        | Cardiotonic Agents:   Cardiac Glycosides Prototype: Digoxin (Lanoxin) "Dig"   Nursing Interventions (1): |  | Definition 
 
        | 
Monitor for S/E, PG/Lactation, MI |  | 
        |  | 
        
        | Term 
 
        | Cardiotonic Agents:   Cardiac Glycosides Prototype: Digoxin (Lanoxin) "Dig"   Apical pulse for 1 min, if HR is __, hold, reuptake pulse. 1hr later, if still __, hold & notify physician: Document, as this may be an indicator of "dig" toxicity. |  | Definition 
 | 
        |  | 
        
        | Term 
 
        | Cardiotonic Agents:   Digoxin Antidote Prototype: ___ |  | Definition 
 
        | Digoxin Immne Fab (Digibind) |  | 
        |  | 
        
        | Term 
 
        | ____: Stays in system a long time (6-8days). Doses can "build up" on each other & causes too high of a level & remember: therapeutic dose is close to toxic dose. |  | Definition 
 | 
        |  | 
        
        | Term 
 
        | Cardiotonic Agents:   Digoxin Antidote Prototype: Digoxin Immune Fab (Digibind)   Normal Value Range: |  | Definition 
 | 
        |  | 
        
        | Term 
 
        | Cardiotonic Agents:   Digoxin Antidote Prototype: Digoxin Immune Fab (Digibind)   Indications (3): Dig Toxicity: |  | Definition 
 
        | Dig Toxicity 
>10 ng/mL & symptomaticK >5 mEq/LDigoxin toxicity s&s: acute- N/V/D & lethargy/ Chronic- S/E of digoxin |  | 
        |  | 
        
        | Term 
 
        | Cardiotonic Agents:   Digoxin Antidote Prototype: Digoxin Immune Fab (Digibind)   Action (1): |  | Definition 
 
        | 
Binds molecules of digoxin, making them unavailable @ their receptor site. It's an antibody found in sheep. |  | 
        |  | 
        
        | Term 
 
        | Cardiotonic Agents:   Digoxin Antidote Prototype: Digoxin Immune Fab (Digibind)   Adverse Effects (3): |  | Definition 
 
        | 
Allergic response to drugReemergence of HF & AFibHypokalemia |  | 
        |  | 
        
        | Term 
 
        | Cardiotonic Agents:   Digoxin Antidote Prototype: Digoxin Immune Fab (Digibind)   Nursing Implications (5): |  | Definition 
 
        | 
Get pt off your floor if possible.Continuous heart monitoringNo telemetryCrash cart by door.DONT look at labwork after giving as the serum level will remain high. |  | 
        |  | 
        
        | Term 
 
        | Cardiotonic Agents:   Phosphodiesterase Inhibitors Prototype:____ |  | Definition 
 | 
        |  | 
        
        | Term 
 
        | Cardiotonic Agents:   Phosphodiesterase Inhibitors Prototype: Inamrinone (Inocor)   Indications (2): |  | Definition 
 
        | 
End stage HF pts who aren't responding to Dig, diuretics, or vasodilators.Given while admitted or schedule out pt clinic- Short term Tx. |  | 
        |  | 
        
        | Term 
 
        | Cardiotonic Agents:   Phosphodiesterase Inhibitors Prototype: Inamrinone (Inocor)   Action (1): |  | Definition 
 
        | 
Increases Ca levels in cardiac cell results in stronger contractions, vasodilation |  | 
        |  | 
        
        | Term 
 
        | Cardiotonic Agents:   Phosphodiesterase Inhibitors Prototype: Inamrinone (Inocor)   Adverse Effects (3): |  | Definition 
 
        | 
HypotensionArrhythmiasBuring @ IV site |  | 
        |  | 
        
        | Term 
 
        | Cardiotonic Agents:   Phosphodiesterase Inhibitors Prototype: Inamrinone (Inocor)   Nursing Implications |  | Definition 
 
        | 
Telemetrys&s of hypotension must be initiated in CCU/ short stay, etc & then can be monitored on the floor.Gradually increase tapering, frequent VS when starting (q 15mins) |  | 
        |  |